Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
28.30
-0.41 (-1.43%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Pfizer
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
3 Surprisingly Underrated Stocks to Buy Right Now
July 26, 2024
These stocks arguably deserve more respect from investors.
Via
The Motley Fool
Freeport-McMoRan, Pfizer, Danaher And An Industrial Stock: CNBC's 'Final Trades'
July 26, 2024
Freeport-McMoRan is Bryn Talkington's "final trade." On July 23, Freeport-McMoRan said second-quarter revenue came in at $6.62 billion.
Via
Benzinga
Get Your Money Out of These 3 Dividend Stocks by 2025
July 26, 2024
Discover the three dividend stocks you should sell by 2025 for better returns. Get insights into why these 3 stocks could disappoint you.
Via
InvestorPlace
What's Going On With Pfizer Stock Thursday?
July 25, 2024
Pfizer is anticipated to report quarterly financial earnings on Tuesday before the market opens. In addition, the European Commission approved Pfizer's DURVEQTIX.
Via
Benzinga
Pfizer's Options: A Look at What the Big Money is Thinking
July 25, 2024
Via
Benzinga
7 Dividend Stocks to Hold On Tight to for the Next Decade
July 25, 2024
Discover the top long-term dividend stocks across pharmaceuticals, asset management, REITs, telecommunications, and tobacco.
Via
InvestorPlace
Check Out What Whales Are Doing With PFE
July 19, 2024
Via
Benzinga
3 Stocks That Can Help You to Get Richer in 2024 and Beyond
July 25, 2024
Good bargains still abound in the market, and two of the stocks below offer fat dividends as well.
Via
The Motley Fool
Beware, Wegovy -- Pfizer Is Working on a Competitor
July 25, 2024
Pfizer wants to maintain its recent run of key approvals.
Via
The Motley Fool
Why Is Sangamo Therapeutics (SGMO) Stock Up 40% Today?
July 24, 2024
Little-known firm Sangamo Therapeutics is surging today, with SGMO stock up more than 40% on promising late-stage trial results.
Via
InvestorPlace
Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study
July 24, 2024
Pfizer's Phase 3 AFFINE study of giroctocogene fitelparvovec gene therapy for hemophilia A meets key endpoints, showing a significant reduction in annualized bleeding rate.
Via
Benzinga
This Promising Weight Loss Drug Candidate Could Be a Huge Growth Catalyst for Pfizer
July 24, 2024
With danuglipron, Pfizer could become a major player in the massive GLP-1 agonist market.
Via
The Motley Fool
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
July 24, 2024
Wegovy, a GLP-1 receptor agonist, had previously been approved for use in obesity treatment and weight management.
Via
Benzinga
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
July 23, 2024
Merck shares topline results from its Phase 2b/3 trial of clesrovimab, showing efficacy in reducing RSV-related infections in infants. Clesrovimab met safety and efficacy endpoints.
Via
Benzinga
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
July 23, 2024
ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's benefit of less weight gain compared to Biktarvy, highlighting its efficacy and patient...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
July 23, 2024
Via
Benzinga
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
July 22, 2024
Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These drugs promise to complement existing injectables, offering new hope in...
Via
Benzinga
Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche
July 22, 2024
Neither is a leader right now, but one of them might be on track to change that.
Via
The Motley Fool
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
July 21, 2024
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.
Via
The Motley Fool
Could Pfizer Become a Top Weight Loss Drug Stock? Don't Count on It.
July 20, 2024
The pharma's latest push to develop a weight loss pill isn't going well.
Via
The Motley Fool
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
July 18, 2024
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry.
Via
Benzinga
COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch
July 18, 2024
Over half of US states have high levels of Covid-19 in wastewater as President Biden isolates with virus. New vaccines expected by Sept.
Via
Benzinga
Exposures
COVID-19
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
July 18, 2024
Johnson & Johnson reports Q2 EPS of $2.82, up 10.2% YoY, beating expectations. Analysts foresee strong MedTech markets ahead, with ongoing M&A strategy emphasizing sustainable growth.
Via
Benzinga
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
July 18, 2024
It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), often referred to as the market’s fear gauge, spiked over 10%, reaching levels...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
July 18, 2024
Pfizer and Valneva announced the completion of the primary vaccination series in the Phase 3 VALOR trial for their Lyme disease vaccine, VLA15. Participants will be monitored until the end of the 2025...
Via
Benzinga
Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio
July 18, 2024
Pfizer Inc (NYSE: PFE) is showing a bullish Golden Cross, indicating potential upward momentum for the stock.
Via
Benzinga
Pfizer, Cisco, Arch Capital And More: CNBC's 'Final Trades'
July 18, 2024
On CNBC's "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said he is staying long on Pfizer Inc.
Via
Benzinga
7 Hated Stocks Set to Make a Major Comeback This Year
July 18, 2024
These seven out-of-favor stocks across various sectors have the potential to stage a significant rebound as market conditions improve.
Via
InvestorPlace
Alnylam Stock Is a Blockbuster Biopharma In the Making
July 18, 2024
Alnylam stock could significantly pad its initial gains if vutrisiran gains expedited approval to hit the market.
Via
InvestorPlace
Time to Pounce: 2 Beaten-Down Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought Right Now
July 18, 2024
Despite their recent underperformance, these two phenomenal dividend stocks -- sporting an average yield of 5.79% -- have the recipes to make their patient shareholders notably richer.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.